VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the initiation of cell line development for its lead BiTAC ® T-cell engager ...

A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a “masked T-cell engager”. This type of immunotherapy ignites our own ...

METiS TechBio (7666.HK), a leading AI-driven drug delivery innovation company, today announced it has entered into an ...

VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager ...

Epkinly was first approved as a monotherapy by the FDA in 2023 for adults with relapsed or refractory DLBCL.

VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced that its scientists will present four posters with data from its T-cell engager programs and platform at the ...

The data presented at today’s summit shows the advances we have made with the RedTail platform and our progress in addressing ...

Kennedy researchers have uncovered key design parameters for bispecific T-cell engagers (TcEs)—a class of cancer immunotherapy drugs. The findings may help unlock the full potential of TcEs and ...

The tumor types we’re focused on are lung, breast and malignant heme. We also have a strong emphasis on colorectal cancer, because there have been more and more cases of earlier diagnosed colorectal ...

EULAR data demonstrated potential for immune reset, including remissions, in both systemic lupus erythematosus (SLE) and ...

Shares of Moderna MRNA have surged 33.5% over the past week, adding nearly $8 billion to the company's market value. The ...